The Cigna Group (NYSE:CI) Shares Acquired by Goldstein Advisors LLC

Goldstein Advisors LLC grew its stake in The Cigna Group (NYSE:CI) by 25.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,083 shares of the health services provider’s stock after purchasing an additional 220 shares during the quarter. Goldstein Advisors LLC’s holdings in The Cigna Group were worth $299,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of CI. ORG Wealth Partners LLC acquired a new position in The Cigna Group during the fourth quarter worth about $34,000. Ulland Investment Advisors LLC boosted its position in The Cigna Group by 2,500.0% during the third quarter. Ulland Investment Advisors LLC now owns 104 shares of the health services provider’s stock worth $36,000 after acquiring an additional 100 shares during the last quarter. Prospera Private Wealth LLC purchased a new position in The Cigna Group during the third quarter worth about $37,000. Harbor Capital Advisors Inc. purchased a new position in The Cigna Group during the third quarter worth about $45,000. Finally, Intact Investment Management Inc. purchased a new position in The Cigna Group during the third quarter worth about $69,000. Institutional investors and hedge funds own 86.99% of the company’s stock.

The Cigna Group Price Performance

Shares of CI opened at $289.04 on Thursday. The Cigna Group has a fifty-two week low of $262.03 and a fifty-two week high of $370.83. The firm’s 50 day moving average price is $298.30 and its 200 day moving average price is $326.03. The company has a market cap of $80.40 billion, a P/E ratio of 27.27, a PEG ratio of 0.78 and a beta of 0.54. The company has a quick ratio of 0.72, a current ratio of 0.72 and a debt-to-equity ratio of 0.71.

The Cigna Group (NYSE:CI) last announced its earnings results on Thursday, October 31st. The health services provider reported $7.51 earnings per share for the quarter, topping the consensus estimate of $7.22 by $0.29. The Cigna Group had a net margin of 1.31% and a return on equity of 18.42%. The firm had revenue of $63.70 billion for the quarter, compared to the consensus estimate of $59.58 billion. During the same period in the prior year, the firm earned $6.77 EPS. The firm’s revenue for the quarter was up 29.8% on a year-over-year basis. On average, research analysts forecast that The Cigna Group will post 28.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Truist Financial reduced their target price on shares of The Cigna Group from $420.00 to $390.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Piper Sandler reaffirmed an “overweight” rating and set a $394.00 target price (up from $392.00) on shares of The Cigna Group in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of The Cigna Group from $398.00 to $394.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. StockNews.com downgraded shares of The Cigna Group from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Finally, Royal Bank of Canada reduced their target price on shares of The Cigna Group from $384.00 to $377.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, The Cigna Group presently has an average rating of “Buy” and an average target price of $395.93.

About The Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.